Nikola Corporation (NASDAQ:NKLA) with the stream of 1.53% also noticed, India Arbutus Biopharma Corporation (NASDAQ:ABUS) encountered a rapid change of 2.27% in the last hour of Tuesday’s trading session.
Nikola Corporation (NASDAQ:NKLA) closed at $9.27 and the price was -40.17% so far this year. The price/earnings to growth ratio (PEG ratio) is a stock’s price-to-earnings (P/E) ratio divided by the growth rate of its earnings for a specified time period.
The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Last traded has a PEG ratio of 0 where as its P/E ratio was 0. The overall volume in the last trading session was 6,287,557 shares.
Nikola Corporation has P/S value of 102601.46 while its P/B esteem remains at 4.21. Likewise, the company has Return on Assets of -46.70%, Return on Equity of -50.90% and Return on Investment of 0. The company demonstrates Gross Margin and Operating Margin of 0 and 0 respectively.
NKLA’s price to sales ratio for trailing twelve months was 102601.46 and price to book ratio for most recent quarter was 4.21, whereas price to cash per share for the most recent quarter was 6.00. The Company’s price to free cash flow for trailing twelve months was recorded as 0.
The NASDAQ -listed company saw a quick ratio for most recent quarter is 0. Analysts mean recommendation for the stock was 2.60. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell. Beta factor, which measures the riskiness of the security, was recorded as 0. A beta of 1 indicates that the security’s price moves with the market.
A beta of less than 1 means that the security is theoretically less volatile than the market. A beta of greater than 1 indicates that the security’s price is theoretically more volatile than the market.
Historical Performances to Consider:
The Stock’s performances for Monthly, weekly, half-yearly, quarterly & year-to-date are mentioned below:-
On a Monthly basis the stock was -34.60%. On a weekly basis, the stock remained -16.70%. The half-yearly performance for the stock has -58.39%, while the quarterly performance was -29.55%. Looking further out we can see that the stock has moved -40.17% over the year to date. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance was stand at 29.59.
Arbutus Biopharma Corporation (NASDAQ:ABUS)
Further, Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) have seen the needle move 2.27% in the most recent session. The NASDAQ-listed company has a yearly EPS of $-0.95 on volume of 394,697 shares. This number is derived from the total net income divided by shares outstanding. In other words, EPS reveals how profitable a company is on a share owner basis.
Volatility is just a proportion of the anticipated day by day value extend—the range where an informal investor works. Greater instability implies more noteworthy benefit or misfortune. After an ongoing check, Arbutus Biopharma Corporation (ABUS) stock is found to be 6.09% volatile for the week, while 5.90% volatility is recorded for the month. The outstanding shares have been calculated 96.87M. Based on a recent bid, its distance from 20 days simple moving average is 1.65% and its distance from 50 days simple moving average is -2.73% while it has a distance of -14.64% from the 200 days simple moving average.
The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 9.40 as current ratio and on the opponent side the debt to equity ratio was 0 and long-term debt to equity ratio also remained 0. The stock showed monthly performance of 7.52%. Likewise, the performance for the quarter was recorded as 5.15% and for the year was -17.58%.
Analysts’ Suggestions to keep an Eye On: In terms of Buy, Sell or Hold recommendations, the stock (ABUS) has analysts’ mean recommendation of 2.20. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
Growth potential is an organization’s future ability to generate larger profits, expand its workforce and increase production. The growth potential generally refers to amount of sales or revenues the organization generates.
In the last five years, the company’s full-year sales growth remained over -21.60% a year on average and the company’s earnings per share moved by an average rate of 6.20%.
Investors focus on the profitability proportions of the company that how the company performs at profitability side. Return on equity ratio or ROE is a significant indicator for prospective investors as they would like to see just how effectively a business is using their cash to produce net earnings.
As a return on equity, Arbutus Biopharma Corporation (NASDAQ:ABUS) produces 177.30%. Because it would be easy and highly flexible, ROI measurement is among the most popular investment ratios. Executives could use it to evaluate the levels of performance on acquisitions of capital equipment whereas investors can determine that how the stock investment is better.
The ROI entry for ABUS’s scenario is at 122.00%. Another main metric of a profitability ratio is the return on assets ratio or ROA that analyses how effectively a business can handle its assets to generate earnings over duration of time. Arbutus Biopharma Corporation (ABUS) generated -61.30% ROA for the trading twelve-month.
The price target set for the stock was $0 and this sets up an interesting set of potential movement for the stock, according to data from FINVIZ’s Research.